Chemotherapy of ovarian cancer: past and present.
D000179:Acrylates / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D006585:Altretamine / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008396:Maryland; D008727:Methotrexate / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy; D011160:Porfiromycin / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011372:Progestins / Q000627:therapeutic use
D000179:Acrylates; D000477:Alkylating Agents; D000970:Antineoplastic Agents; D011372:Progestins; D003609:Dactinomycin; D011344:Procarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011160:Porfiromycin; D006585:Altretamine; D005472:Fluorouracil; D008727:Methotrexate